Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro

Antimicrob Agents Chemother. 2008 Jan;52(1):329-32. doi: 10.1128/AAC.01004-07. Epub 2007 Oct 29.

Abstract

Using an indicator cell assay that directly quantifies viral replication, we show that human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2, respectively) exhibit similar sensitivities to 3'-azido-3'-deoxythymidine (zidovudine) as well as other nucleoside analog inhibitors of reverse transcriptase. These data support the use of nucleoside analogs for antiviral therapy of HIV-2 infection.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • HIV-1 / drug effects*
  • HIV-1 / physiology
  • HIV-2 / drug effects*
  • HIV-2 / physiology
  • HeLa Cells
  • Humans
  • Microbial Sensitivity Tests / methods
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Zidovudine / pharmacology*

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Zidovudine